Woodstock Corp’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.8M Sell
18,345
-775
-4% -$183K 0.48% 58
2026
Q1
$3.82M Sell
19,120
-885
-4% -$175K 0.34% 68
2025
Q4
$3.78M Sell
20,005
-20
-0.1% -$3.84K 0.32% 67
2025
Q3
$3.55M Sell
20,025
-9,472
-32% -$1.41M 0.31% 71
2025
Q2
$3.35M Buy
29,497
+100
+0.3% +$10.7K 0.31% 72
2025
Q1
$3.09M Sell
29,397
-14
-0% -$1.58K 0.31% 73
2024
Q4
$3.15M Buy
29,411
+200
+0.7% +$22.6K 0.3% 71
2024
Q3
$2.92M Buy
29,211
+100
+0.3% +$10.1K 0.28% 77
2024
Q2
$2.45M Sell
29,111
-1,000
-3% -$79.6K 0.25% 78
2024
Q1
$2.2M Hold
30,111
0.23% 82
2023
Q4
$2.15M Sell
30,111
-4,049
-12% -$239K 0.25% 79
2023
Q3
$2.05M Sell
34,160
-12,635
-27% -$832K 0.26% 76
2023
Q2
$3.37M Sell
46,795
-5,809
-11% -$436K 0.4% 65
2023
Q1
$3.87M Sell
52,604
-2,410
-4% -$171K 0.49% 59
2022
Q4
$3.67M Sell
55,014
-43,881
-44% -$2.85M 0.49% 61
2022
Q3
$5.31M Sell
98,895
-3,537
-3% -$208K 0.79% 47
2022
Q2
$5.7M Sell
102,432
-240
-0.2% -$13.6K 0.79% 48
2022
Q1
$7.21M Sell
102,672
-7,400
-7% -$537K 0.84% 40
2021
Q4
$10.6M Hold
110,072
1.11% 30
2021
Q3
$9.57M Sell
110,072
-176
-0.2% -$13.6K 1.12% 32
2021
Q2
$9.02M Hold
110,248
1.06% 35
2021
Q1
$10.5M Sell
110,248
-1,133
-1% -$107K 1.33% 27
2020
Q4
$6.91M Buy
111,381
+32
+0% +$1.82K 0.92% 38
2020
Q3
$6.62M Sell
111,349
-2,341
-2% -$160K 1.07% 34
2020
Q2
$7.93M Buy
113,690
+170
+0.1% +$10.8K 1.35% 29
2020
Q1
$5.15M Sell
113,520
-1,077
-0.9% -$61K 1.05% 36
2019
Q4
$7.46M Buy
114,597
+386
+0.3% +$25.8K 1.21% 36
2019
Q3
$7.09M Buy
114,211
+105
+0.1% +$6.59K 1.24% 31
2019
Q2
$8.13M Buy
114,106
+689
+0.6% +$50.7K 1.42% 24
2019
Q1
$8.89M Buy
113,417
+1,593
+1% +$121K 1.59% 22
2018
Q4
$9.47M Buy
111,824
+4,891
+5% +$521K 1.9% 13
2018
Q3
$18.3M Sell
106,933
-1,904
-2% -$287K 3.09% 4
2018
Q2
$14.1M Sell
108,837
-1,724
-2% -$192K 2.59% 4
2018
Q1
$11.4M Sell
110,561
-283
-0.3% -$28K 2.15% 7
2017
Q4
$9.47M Buy
110,844
+341
+0.3% +$29.6K 1.75% 18
2017
Q3
$9.39M Buy
110,503
+1,170
+1% +$92.6K 1.79% 16
2017
Q2
$8.28M Buy
109,333
+2,068
+2% +$145K 1.62% 23
2017
Q1
$7.08M Buy
107,265
+1,004
+0.9% +$66K 1.43% 29
2016
Q4
$6.74M Sell
106,261
-1,372
-1% -$86.6K 1.37% 30
2016
Q3
$6.85M Sell
107,633
-3,035
-3% -$223K 1.4% 30
2016
Q2
$8.23M Sell
110,668
-577
-0.5% -$42.8K 1.7% 17
2016
Q1
$7.43M Hold
111,245
1.56% 21
2015
Q4
$7.52M Sell
111,245
-1,194
-1% -$73.7K 1.65% 17
2015
Q3
$6.01M Sell
112,439
-2,084
-2% -$126K 1.37% 27
2015
Q2
$7.21M Buy
114,523
+449
+0.4% +$24.5K 1.36% 29
2015
Q1
$5.49M Buy
114,074
+19,685
+21% +$754K 1.02% 41
2014
Q4
$3.13M Buy
94,389
+10,668
+13% +$347K 0.58% 59
2014
Q3
$2.45M Buy
83,721
+23,764
+40% +$789K 0.47% 65
2014
Q2
$2.33M Buy
59,957
+18,050
+43% +$732K 0.41% 73
2014
Q1
$1.76M Buy
41,907
+27,754
+196% +$1.16M 0.33% 83
2013
Q4
$464K Buy
+14,153
New +$461K 0.08% 123

Other funds holding LGND

Woodstock Corp's LGND Position: Q2 2026 in Review

Woodstock Corp reduced its Ligand Pharmaceuticals (LGND) stake by 4.1% in Q2 2026, selling an estimated $183K and leaving 18,345 shares worth $5.8M. The position accounts for 0.48% of the portfolio, ranked #58.

Woodstock Corp first reported a position in LGND in Q4 2013 and has held it in 51 quarters since. The position peaked at $18.3M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Woodstock Corp held 18,345 shares of Ligand Pharmaceuticals worth $5.8M as of Q2 2026.
  • Woodstock Corp sold 775 Ligand Pharmaceuticals shares in Q2 2026, an estimated $183K.
  • Ligand Pharmaceuticals made up 0.48% of Woodstock Corp's portfolio in Q2 2026, its #58 holding.
  • Woodstock Corp first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 51 quarters since.
  • Woodstock Corp's Ligand Pharmaceuticals position peaked at $18.3M in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Woodstock Corp's 13F filing for Q2 2026, filed 13 Jul 2026.